Adverum Biotechnologies, Inc.
ADVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $4 | $0 | $8 |
| % Growth | -72.2% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $4 | $0 | $8 |
| % Margin | 100% | 100% | – | 100% |
| R&D Expenses | $77 | $77 | $99 | $89 |
| G&A Expenses | $63 | $55 | $58 | $64 |
| SG&A Expenses | $63 | $55 | $58 | $64 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $140 | $133 | $157 | $154 |
| Operating Income | -$139 | -$129 | -$157 | -$146 |
| % Margin | -13,915.9% | -3,581.7% | – | -1,948.3% |
| Other Income/Exp. Net | $8 | $6 | $3 | $1 |
| Pre-Tax Income | -$131 | -$123 | -$154 | -$146 |
| Tax Expense | $0 | -$1 | $0 | $0 |
| Net Income | -$131 | -$122 | -$155 | -$146 |
| % Margin | -13,092.7% | -3,392.1% | – | -1,940.5% |
| EPS | -6.62 | -2.02 | -2.67 | -1.48 |
| % Growth | -227.7% | 24.3% | -80.4% | – |
| EPS Diluted | -6.62 | -2.02 | -2.67 | -1.48 |
| Weighted Avg Shares Out | 20 | 58 | 58 | 98 |
| Weighted Avg Shares Out Dil | 20 | 58 | 58 | 98 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $6 | $7 | $5 |
| EBITDA | -$136 | -$123 | -$151 | -$141 |
| % Margin | -13,550.6% | -3,424.9% | – | -1,886.4% |